A study to determine the optimal dose of Tarceva [erlotinib], given sequentially to vinorelbine and Xeloda [capecitabine], as first/second-line chemotherapy in patients with metastatic breast cancer
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Capecitabine; Erlotinib; Vinorelbine
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche website.
- 24 Apr 2007 New trial record.